Oculis (OCS) Expected to Release Earnings on Thursday

Oculis (NASDAQ:OCS) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Oculis to post earnings of ($0.48) per share and revenue of $0.2340 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Stock Performance

Oculis stock opened at $10.84 on Thursday. Oculis has a 12-month low of $10.52 and a 12-month high of $34.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The company has a market capitalization of $628.50 million, a price-to-earnings ratio of -5.09 and a beta of 0.44. The firm’s fifty day moving average price is $14.54 and its 200 day moving average price is $22.88.

Analyst Ratings Changes

Several brokerages have recently weighed in on OCS. Wall Street Zen downgraded Oculis from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. Guggenheim cut their price target on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. JPMorgan Chase & Co. reduced their price target on Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Robert W. Baird lowered their price objective on Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research note on Monday, June 1st. Finally, HC Wainwright restated a “buy” rating on shares of Oculis in a report on Thursday, June 11th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oculis presently has an average rating of “Moderate Buy” and an average target price of $38.33.

Hedge Funds Weigh In On Oculis

Hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC acquired a new position in Oculis in the fourth quarter worth about $9,862,000. Millennium Management LLC acquired a new stake in Oculis during the fourth quarter valued at approximately $312,000. Marshall Wace LLP acquired a new stake in Oculis during the fourth quarter valued at approximately $914,000. Alyeska Investment Group L.P. lifted its holdings in Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after buying an additional 200,000 shares during the last quarter. Finally, HRT Financial LP bought a new position in Oculis during the 4th quarter worth approximately $876,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.